We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+9.37%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$750M
AUM Growth
+$14.3M
Cap. Flow
+$49M
Cap. Flow %
6.53%
Top 10 Hldgs %
50.53%
Holding
71
New
20
Increased
16
Reduced
11
Closed
15

Top Buys

Rank Stock Value
1
RCKT icon
Rocket Pharmaceuticals
RCKT
+$31.4M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$17.5M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$15M
4
ROIV icon
Roivant Sciences
ROIV
+$13.6M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$12.7M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$28.5M
2
ACLX
Arcellx
ACLX
+$15.8M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$15.8M
4
RCUS icon
Arcus Biosciences
RCUS
+$15.2M
5
IMVT icon
Immunovant
IMVT
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 93.46%
2 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMVT icon
1
Immunovant
IMVT
$8.27B
$61.4M 8.19%
1,600,000
-650,000
-29% -$14.7M
IDYA icon
2
IDEAYA Biosciences
IDYA
$3.5B
$60.7M 8.1%
2,250,000
+500,000
+29% +$12.7M
OLMA icon
3
Olema Pharmaceuticals
OLMA
$1.07B
$46.2M 6.17%
3,743,875
– –
RCKT icon
4
Rocket Pharmaceuticals
RCKT
$357M
$40.5M 5.4%
1,975,000
+1,725,000
+690% +$31.4M
CYTK icon
5
Cytokinetics
CYTK
$10.9B
$36.8M 4.91%
1,250,000
-400,000
-24% -$13.3M
AKRO
6
DELISTED
Akero Therapeutics
AKRO
$30.3M 4.05%
600,000
+80,000
+15% +$3.72M
APLS
7
DELISTED
Apellis Pharmaceuticals
APLS
$28.5M 3.81%
750,000
+125,000
+20% +$5.49M
GPCR icon
8
Structure Therapeutics
GPCR
$3.53B
$25.2M 3.36%
500,000
+100,000
+25% +$3.22M
APLS
9
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$24.7M 3.3%
+650,000
New +$28.6M
SRPT icon
10
Sarepta Therapeutics
SRPT
$1.7B
$24.2M 3.23%
200,000
-100,000
-33% -$11.3M
IMCR icon
11
Immunocore
IMCR
$1.78B
$23.4M 3.12%
450,000
-50,000
-10% -$2.96M
ICVX
12
DELISTED
Icosavax, Inc. Common Stock
ICVX
$21.4M 2.86%
2,765,741
+600,000
+28% +$4.98M
DYN icon
13
Dyne Therapeutics
DYN
$4.2B
$19.5M 2.61%
2,180,000
+400,000
+22% +$4.31M
KRTX
14
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$19.4M 2.59%
115,000
+80,000
+229% +$15M
NBIX icon
15
Neurocrine Biosciences
NBIX
$17.9B
$16.9M 2.25%
150,000
-150,000
-50% -$15.8M
VRDN icon
16
Viridian Therapeutics
VRDN
$2.18B
$16.1M 2.15%
1,050,000
-75,000
-7% -$1.43M
XENE icon
17
Xenon Pharmaceuticals
XENE
$6.36B
$15.4M 2.05%
450,000
+175,000
+64% +$6.55M
CERE
18
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$15.3M 2.04%
+700,000
New +$17.5M
ROIV icon
19
Roivant Sciences
ROIV
$25.3B
$14M 1.87%
+1,200,000
New +$13.6M
BBIO icon
20
CALL
BridgeBio Pharma
BBIO
$16.9B
$13.2M 1.76%
500,000
-150,000
-23% -$4.26M
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$13.1M 1.74%
+300,000
New +$10.7M
ANNX icon
22
Annexon
ANNX
$867M
$12.5M 1.67%
5,300,000
+1,800,000
+51% +$5.44M
IMTX icon
23
Immatics
IMTX
$1.25B
$12.2M 1.62%
1,050,000
+550,000
+110% +$6.56M
DSGN icon
24
Design Therapeutics
DSGN
$748M
$11.9M 1.58%
5,032,501
+2,235,000
+80% +$10.4M
ALLK
25
DELISTED
Allakos
ALLK
$10.6M 1.41%
4,650,000
-600,000
-11% -$2.23M
1
2 3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q3 2023 Portfolio in Review

As of Q3 2023, Logos Global Management held 71 positions worth $750M, up 1.9% from $735M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Logos Global Management deployed $49M of net new capital in Q3 2023, opening 20 new positions and adding to 16 existing holdings. Its largest new stake was Cerevel Therapeutics Holdings, Inc. Common Stock: 700,000 shares worth $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $15.8M trimmed.

  • Logos Global Management's largest Q3 2023 buy was Cerevel Therapeutics Holdings, Inc. Common Stock: 700,000 shares worth $15.3M.
  • Logos Global Management added most to Rocket Pharmaceuticals in Q3 2023, an estimated $31.4M increase.
  • Logos Global Management's biggest Q3 2023 reduction was Neurocrine Biosciences, cutting an estimated $15.8M.
  • Logos Global Management fully exited Biogen in Q3 2023, selling an estimated $28.5M.
  • Logos Global Management's ten largest holdings make up 51% of its $750M portfolio in Q3 2023.
  • Logos Global Management opened 20 new positions and closed 15 in Q3 2023.
  • Logos Global Management's portfolio value rose 1.9% quarter-over-quarter to $750M.

Based on Logos Global Management's 13F filing for Q3 2023, filed 14 Nov 2023.